KR20120003499A - 클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조 - Google Patents

클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조 Download PDF

Info

Publication number
KR20120003499A
KR20120003499A KR1020117030103A KR20117030103A KR20120003499A KR 20120003499 A KR20120003499 A KR 20120003499A KR 1020117030103 A KR1020117030103 A KR 1020117030103A KR 20117030103 A KR20117030103 A KR 20117030103A KR 20120003499 A KR20120003499 A KR 20120003499A
Authority
KR
South Korea
Prior art keywords
methyl
alkyl
triazol
yloxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117030103A
Other languages
English (en)
Korean (ko)
Inventor
하르트무트 씨 콜브
조셉 씨. 월쉬
다나라크쉬미 카시
바니 모차르라
빙 왕
우메쉬 비. 간가다르마트
브라이언 에이. 듀클로스
카이 첸
웨이 장
강 첸
헨리 클리프튼 패짓
파라드 카리미
피터 제이. 에이치. 스콧
지용 가오
퀴안와 리앙
토마스 리 콜리어
티에밍 자오
춘팡 시아
Original Assignee
지멘스 메디컬 솔루션즈 유에스에이, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지멘스 메디컬 솔루션즈 유에스에이, 인크. filed Critical 지멘스 메디컬 솔루션즈 유에스에이, 인크.
Publication of KR20120003499A publication Critical patent/KR20120003499A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020117030103A 2007-04-05 2008-04-07 클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조 Withdrawn KR20120003499A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92206507P 2007-04-05 2007-04-05
US60/922,065 2007-04-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020097022869A Division KR20090127433A (ko) 2007-04-05 2008-04-07 클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조

Publications (1)

Publication Number Publication Date
KR20120003499A true KR20120003499A (ko) 2012-01-10

Family

ID=39743771

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117030103A Withdrawn KR20120003499A (ko) 2007-04-05 2008-04-07 클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조
KR1020097022869A Ceased KR20090127433A (ko) 2007-04-05 2008-04-07 클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097022869A Ceased KR20090127433A (ko) 2007-04-05 2008-04-07 클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조

Country Status (7)

Country Link
US (2) US7829063B2 (enExample)
EP (2) EP2468734A1 (enExample)
JP (1) JP2010523599A (enExample)
KR (2) KR20120003499A (enExample)
CN (1) CN101679318A (enExample)
CA (1) CA2683434A1 (enExample)
WO (1) WO2008124703A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2703981A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Heterocyclic urea and thiourea derivatives and methods of use thereof
EP2240171B1 (en) * 2008-01-09 2014-08-13 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase IX
US8562945B2 (en) 2008-01-09 2013-10-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
BRPI0923305B1 (pt) 2008-12-09 2019-01-22 Gilead Sciences Inc moduladores de receptores toll-like, seu uso e composição farmacêutica que os compreende
BR112012000210A2 (pt) 2009-06-15 2019-09-24 Molecular Insight Pharm Inc processo para a produção de heterodímeoros de ácido glutâmico.
US9914745B2 (en) 2009-08-14 2018-03-13 Indian Association For The Cultivation Of Science Morpholino-based antisense agent
WO2011047796A1 (en) * 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
US10639608B2 (en) 2010-04-08 2020-05-05 Siemens Medical Solutions Usa, Inc. System, device and method for preparing tracers and transferring materials during radiosynthesis
EP2556372A1 (en) * 2010-04-08 2013-02-13 Siemens Medical Solutions USA, Inc. Synthesis of 18f-labeled tracers in hydrous organic solvents
BR112013010333A2 (pt) * 2010-10-29 2017-07-25 Clino Ltd sonda de imageamento de tau
BR112013011830B1 (pt) * 2010-11-13 2022-03-15 Innocrin Pharmaceuticals, Inc Composto inibidor de metaloenzima, composição que compreende o dito composto, bem como uso do mesmo para tratar uma doença ou transtorno relacionado à metaloenzima
WO2012118715A2 (en) * 2011-02-28 2012-09-07 The Board Of Trustees Of Leland Stanford Junior University Non-peptidic quenched fluorescent imaging probes
CN102219753B (zh) * 2011-04-21 2012-10-31 山东大学 一种三氮唑类化合物及其制备方法与应用
CN110204478A (zh) 2011-05-09 2019-09-06 文森医学公司 碳酸酐酶靶向剂及其使用方法
JP2014156400A (ja) * 2011-05-24 2014-08-28 Astellas Pharma Inc 腫瘍の画像診断用標識誘導体
EP2800471A4 (en) 2012-01-06 2015-11-04 Molecular Insight Pharm Inc METAL COMPLEX OF POLY (CARBOXYL) AMINE CONTAINING LIGANDS HAVING AFFINITY FOR CARBON IX ANHYDRASE
EP2831264B1 (en) 2012-03-30 2019-07-10 VisEn Medical, Inc. Bacterial imaging agents and methods of using same
EP3545978B1 (en) 2013-01-14 2021-09-08 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
TW201609674A (zh) 2013-11-05 2016-03-16 拜耳作物科學股份有限公司 用於控制節肢動物的新穎化合物（二）
ES2930667T3 (es) 2014-07-11 2022-12-21 Gilead Sciences Inc Moduladores de receptores de tipo Toll para el tratamiento de VIH
CN104212440B (zh) * 2014-09-03 2016-03-30 无锡艾德美特生物科技有限公司 一类喹唑啉类荧光探针及其制备和应用
JP2017526730A (ja) 2014-09-16 2017-09-14 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体モジュレーターの固体形態
TWI780423B (zh) * 2014-09-16 2022-10-11 美商基利科學股份有限公司 類鐸受體調節劑的製備方法
AU2016236239B2 (en) 2015-03-24 2020-06-25 H. Lundbeck A/S Manufacture of 4,5,6,7-tetrahydroisozaxolo[5,4-c]pyridin-3-ol
LT6401B (lt) 2015-07-28 2017-06-12 Vilniaus Universitetas Karboanhidrazės selektyvūs inhibitoriai
CN105541825A (zh) * 2015-12-28 2016-05-04 中国药科大学 三氮唑衍生物制备方法及其作为药物的用途
AU2017263630B2 (en) * 2016-05-13 2021-11-04 The Johns Hopkins University Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase IX and uses thereof
US10695450B2 (en) 2016-07-26 2020-06-30 Laboratoires Cyclopharma Synthesis of a radioactive agent composition
CN110785414A (zh) * 2017-04-20 2020-02-11 加利福尼亚大学董事会 K-Ras调节剂
CA3072854A1 (en) * 2017-08-17 2019-02-21 Glaxosmithkline Intellectual Property Development Limited Novel tetrazole compounds and their use in the treatment of tuberculosis
KR102147971B1 (ko) * 2019-11-22 2020-08-25 국방과학연구소 반응용매에 대한 혼화성 차이를 이용한 화학선택적 트리아졸의 제조방법
WO2025113696A1 (zh) * 2023-11-30 2025-06-05 赣州和美药业股份有限公司 一种化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
WO2004048544A2 (en) * 2002-11-26 2004-06-10 Bayer Healthcare Ca ix-specific inhibitors
US20060269942A1 (en) * 2005-04-27 2006-11-30 Kolb Hartmuth C In situ click chemistry method for screening high affinity molecular imaging probes
EP1733742A1 (en) 2005-06-17 2006-12-20 Universiteit Utrecht Holding B.V. Dendrimers multivalently substituted with active groups
WO2007018431A2 (en) 2005-08-05 2007-02-15 Syntarga B.V. Triazole-containing releasable linkers and conjugates comprising the same
US8470587B2 (en) * 2006-08-28 2013-06-25 The Trustees Of The University Of Pennsylvania 129Xe biosensors and their use
WO2008033557A2 (en) 2006-09-15 2008-03-20 Siemens Medical Solutions Usa, Inc. Click chemistry-derived cyclic peptidomimetics as integrin markers

Also Published As

Publication number Publication date
KR20090127433A (ko) 2009-12-11
WO2008124703A2 (en) 2008-10-16
EP2468734A1 (en) 2012-06-27
US20090123372A1 (en) 2009-05-14
CA2683434A1 (en) 2008-10-16
US7829063B2 (en) 2010-11-09
WO2008124703A3 (en) 2009-02-05
US8354092B2 (en) 2013-01-15
CN101679318A (zh) 2010-03-24
EP2129666A2 (en) 2009-12-09
US20100317842A1 (en) 2010-12-16
JP2010523599A (ja) 2010-07-15

Similar Documents

Publication Publication Date Title
KR20120003499A (ko) 클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조
US20250122194A1 (en) Novel small molecule inhibitors of tead transcription factors
JP6887996B2 (ja) Ｔｅａｄ転写因子自己パルミトイル化阻害剤
KR101523257B1 (ko) 니트로-이미다졸 저산소증 영상화제
US9586947B2 (en) Imidazoline derivatives, preparation methods thereof, and their applications in medicine
BR112021014977A2 (pt) Derivados de acetamido como inibidores de dna polimerase teta
JP2002539115A (ja) タンパク質チロシンホスファターゼ阻害剤
CA2843836A1 (en) Uracil derivative and use thereof for medical purposes
US12240855B2 (en) Pyrrolopyrazole derivative
AU2015231053B2 (en) Compounds and their methods of use
US20230052551A1 (en) Fluorescent probe for detection of enpp activity
JP7774897B2 (ja) 窒素含有化合物、前記窒素含有化合物を含む組成物、及び腫瘍悪性度の予測マーカー
EP4269400B1 (en) Ykl-40 inhibitors and their therapeutic applications
TW202235077A (zh) Usp7結合存活靶向嵌合(surtac)分子及其用途
US20230414794A1 (en) Psma inhibitor, compound and application
Song et al. Design, Synthesis, and Biological Evaluation of Resorcinol-Based Novel (2r, 4r)-Phenylproline Derivatives as Potent Hsp90 Inhibitors
WO2016205031A1 (en) Fluoropyridyl pyrazol compounds

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20111215

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid